GeoVax Relocates Headquarters and Labs to Atlanta Area to Support Growth and Pipeline Advancement

GeoVax Labs, Inc. announced the relocation of its corporate headquarters and laboratory operations to new facilities in the Atlanta metropolitan area, positioning the clinical-stage biotechnology company for accelerated growth and pipeline advancement. The moves, scheduled for completion in the fourth quarter of 2025, will support GeoVax's expanding pipeline and preparation for product commercialization.

The company's laboratory group will relocate to Science Square / Portal Innovations in midtown Atlanta, providing expanded access to modern laboratories and collaborative research environments designed to accelerate innovation. The corporate headquarters will move to 1955 Lake Park Drive in Smyrna, Georgia, establishing a new hub for corporate operations and leadership activities.

David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that these moves represent a significant milestone in the company's evolution. By placing research and development teams in one of the most dynamic bio-research ecosystems in the Southeast and expanding administrative capabilities, GeoVax is positioning itself for accelerated growth. These facilities will support the company's broad and advancing pipeline, including the promising GEO-MVA program and multiple clinical trials in cancer therapy and infectious disease vaccines.

Eddie Lai, Director of Business Development at Atlanta Portal Innovations, expressed excitement about GeoVax joining the innovation ecosystem at Science Square Labs. He noted that GeoVax brings a strong legacy of innovation rooted in the Southeast to the Portal Innovations network, which includes more than 100 innovative companies utilizing sites across the country. As an innovation engine, Portal Innovations supports scientific companies in all stages of development, providing both research and development capabilities and administrative support.

The relocations underscore GeoVax's trajectory as a company focused on long-term growth, scientific advancement, and future commercialization opportunities. As the company builds momentum with a deepening pipeline and strategic partnerships, the enhanced infrastructure will provide a strong foundation to meet global healthcare needs. For more information about the company's clinical trials and updates, visit https://www.geovax.com.

This strategic move is important because it demonstrates the maturation of Georgia's biotechnology sector and highlights how infrastructure investments can accelerate medical innovation. For patients awaiting new cancer therapies and improved vaccines, GeoVax's expansion signals potential advancement in treatments for conditions ranging from solid tumors to infectious diseases like COVID-19 and Mpox. The relocation strengthens ties within the regional bio-ecosystem, potentially creating collaborative opportunities that could speed development of life-saving medical technologies.